<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="3893grid.411784.fLiver Department, Cochin Hospital, [10], [11], [12], 0000000121633745grid.3575.4Global Hepatitis Programme," exact="World Health Organization" post="(WHO), [13], 0000 0001 2240 3300grid.10388.32Department of Medicine I,"/>
 <result pre="hepatitis B, and 15 million with hepatitis C, in the" exact="World Health Organization" post="(WHO) European Region [1–4]. The prevalence of chronic hepatitis"/>
 <result pre="Virus HCV Hepatitis C Virus HDV Hepatitis D Virus WHO" exact="World Health Organization" post="1Case definitions for hepatitis B and C vary across"/>
 <result pre="to the Community network under Decision No 2119/98/EC of the" exact="European Parliament" post="and of the Council. Acknowledgements European Consensus Working Group"/>
 <result pre="Maria Buti, EASL, Barcelona; Stefan Mauss, EASL, Düsseldorf; Erika Duffell," exact="European Centre for Disease Prevention and Control" post="(ECDC); Stefan Wiktor, Team Lead, Global Hepatitis Programme, World"/>
 <result pre="and Control (ECDC); Stefan Wiktor, Team Lead, Global Hepatitis Programme," exact="World Health Organization" post="(WHO), Geneva; Antons Mozalevskis, WHO Regional Office for Europe,"/>
 <result pre="The HIV in Europe initiative has received unrestricted funding from" exact="Gilead Sciences," post="Merck, Tibotec, Pfizer, Schering-Plough, Abbott, Boehringer Ingelheim, Bristol-Myers Squibb,"/>
 <result pre="unrestricted funding from Gilead Sciences, Merck, Tibotec, Pfizer, Schering-Plough, Abbott," exact="Boehringer Ingelheim," post="Bristol-Myers Squibb, GlaxoSmithKline, and ViiV Healthcare. The operational procedures"/>
 <result pre="from Gilead Sciences, Merck, Tibotec, Pfizer, Schering-Plough, Abbott, Boehringer Ingelheim," exact="Bristol-Myers Squibb," post="GlaxoSmithKline, and ViiV Healthcare. The operational procedures within the"/>
 <result pre="framework of the Second Health Programme (2008–2013), and the Danish" exact="National Research Foundation" post="(grant number DNRF126). The funders had no role in"/>
 <result pre="has received honoraria for speaking and advisory boards from AbbVie," exact="Bristol-Myers Squibb" post="(BMS), Gilead, Janssen, Merck Sharp and Dohme (MSD), and"/>
 <result pre="and advisory boards from AbbVie, Bristol-Myers Squibb (BMS), Gilead, Janssen," exact="Merck" post="Sharp and Dohme (MSD), and ViiV Healthcare; SP has"/>
 <result pre="speaking and advisory boards from Abbott, Abbvie, Gilead, Hexal, Janssen," exact="Merck" post="and ViiV; JVL has received speaker fees and/or research"/>
 <result pre="JVL has received speaker fees and/or research grants from AbbVie," exact="Gilead Sciences," post="and MSD; ES has received grants/research support from AbbVie,"/>
 <result pre="in the WHO European region. Fact sheet July 2015 [Internet]." exact="World Health Organization;" post="2015. http://www.euro.who.int/__data/assets/pdf_file/0010/283357/fact-sheet-en-hep-c.pdf?ua=1. Accessed [03 Apr 2017]. 2.HopeVDEramovaICapurroDDonoghoeMCPrevalence and estimation"/>
</results>
